BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis

Summary

This Phase 2b study is designed to evaluate the efficacy and safety of BG9924 given subcutaneously (SC) versus placebo in participants with active rheumatoid arthritis (RA) who have previously had an inadequate response to treatment with anti-tumor necrosis factor (anti-TNF) therapy.

Timeline

Start

2007-03

Primary completion

2008-10

Completion

2008-10

Outcome

Outcome not reported

Stopped: “Interim analysis of data failed to meet primary endpoint.”

Drugs

Indications